158 related articles for article (PubMed ID: 33624271)
1. Cost-Effectiveness of Pembrolizumab for the Adjuvant Treatment of Melanoma Patients with Lymph Node Involvement Who Have Undergone Complete Resection in Argentina.
Wurcel V; Scherrer E; Aguiar-Ibanez R; Altuna JI; Carabajal F; Jain S; Baluni G
Oncol Ther; 2021 Jun; 9(1):167-185. PubMed ID: 33624271
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of Pembrolizumab as an Adjuvant Treatment in Colombia for Melanoma Patients with Lymph Node Involvement After Complete Resection.
Lopez-Vinueza C; Urrego-Reyes J; Gutierrez FRS; Wurcel V; Zhang S; Jiang S; Jiang R; Zambrano Harvey A; Dhankhar P; Sawhney B; Baluni G; Jain S; Bhadra D
Adv Ther; 2023 Jun; 40(6):2836-2854. PubMed ID: 37129772
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States.
Bensimon AG; Zhou ZY; Jenkins M; Song Y; Gao W; Signorovitch J; Krepler C; Liu FX; Wang J; Aguiar-Ibáñez R
J Med Econ; 2019 Oct; 22(10):981-993. PubMed ID: 31012765
[No Abstract] [Full Text] [Related]
4. Cost-effectiveness of pembrolizumab as an adjuvant treatment for patients with resected stage IIB or IIC melanoma in Switzerland.
Favre-Bulle A; Bencina G; Zhang S; Jiang R; Andritschke D; Bhadhuri A
J Med Econ; 2023; 26(1):283-292. PubMed ID: 36748342
[TBL] [Abstract][Full Text] [Related]
5. An Economic Evaluation of Pembrolizumab Versus Other Adjuvant Treatment Strategies for Resected High-Risk Stage III Melanoma in the USA.
Bensimon AG; Zhou ZY; Jenkins M; Song Y; Gao W; Signorovitch J; Krepler C; Scherrer E; Wang J; Aguiar-Ibáñez R
Clin Drug Investig; 2020 Jul; 40(7):629-643. PubMed ID: 32418051
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness of Pembrolizumab Regimens for the First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma in Argentina.
Wurcel V; Chirovsky D; Borse R; Altuna JI; Carabajal F; Gandhi J
Adv Ther; 2021 May; 38(5):2613-2630. PubMed ID: 33855690
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Resected Stage IIB or IIC Melanoma in the United States.
Zhang S; Bensimon AG; Xu R; Jiang R; Greatsinger A; Zhang A; Fukunaga-Kalabis M; Krepler C
Adv Ther; 2023 Jul; 40(7):3038-3055. PubMed ID: 37191852
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage III Melanoma in Medicare Patients.
Mojtahed SA; Boyer NR; Rao SA; Gajewski TF; Tseng J; Turaga KK
Ann Surg Oncol; 2021 Dec; 28(13):9039-9047. PubMed ID: 34129153
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of pembrolizumab compared to standard of care as first line treatment for patients with advanced melanoma in Hong Kong.
Loong HH; Wong CKH; Leung LKS; Tan SC; Jen J; Lee MYK; Aguiar-Ibáñez R; Wang J
Cost Eff Resour Alloc; 2020; 18():2. PubMed ID: 31969794
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Renal Cell Carcinoma Post-nephrectomy in the United States.
Lai Y; Bensimon AG; Gao E; Bhattacharya R; Xu R; Chevure J; Imai K; Haas NB
Clin Genitourin Cancer; 2023 Oct; 21(5):612.e1-612.e11. PubMed ID: 37137809
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US healthcare payer perspective.
Gerbasi ME; Stellato D; Ghate SR; Ndife B; Moynahan A; Mishra D; Gunda P; Koruth R; Delea TE
J Med Econ; 2019 Dec; 22(12):1243-1252. PubMed ID: 31223037
[No Abstract] [Full Text] [Related]
12. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden.
Srivastava T; Prabhu VS; Li H; Xu R; Zarabi N; Zhong Y; Pellissier JM; Perini RF; de Wit R; Mamtani R
Eur Urol Oncol; 2020 Oct; 3(5):663-670. PubMed ID: 31412001
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States.
Huang M; A Fasching P; Haiderali A; Xue W; Yang C; Pan W; Zhou ZY; Hu P; Chaudhuri M; Le Bailly De Tilleghem C; Cappoen N; O'Shaughnessy J
Adv Ther; 2023 Mar; 40(3):1153-1170. PubMed ID: 36648737
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness of Neoadjuvant Pembrolizumab plus Chemotherapy Followed by Adjuvant Pembrolizumab in Patients with High-Risk, Early-Stage, Triple-Negative Breast Cancer in Switzerland.
Favre-Bulle A; Huang M; Haiderali A; Bhadhuri A
Pharmacoecon Open; 2024 Jan; 8(1):91-101. PubMed ID: 37999854
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of adjuvant systemic therapies for patients with high-risk melanoma in Europe: a model-based economic evaluation.
Mulder EEAP; Smit L; Grünhagen DJ; Verhoef C; Sleijfer S; van der Veldt AAM; Uyl-de Groot CA
ESMO Open; 2021 Dec; 6(6):100303. PubMed ID: 34781194
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer.
Georgieva M; da Silveira Nogueira Lima JP; Aguiar P; de Lima Lopes G; Haaland B
Lung Cancer; 2018 Oct; 124():248-254. PubMed ID: 30268469
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer.
Sarfaty M; Hall PS; Chan KKW; Virik K; Leshno M; Gordon N; Moore A; Neiman V; Rosenbaum E; Goldstein DA
Eur Urol; 2018 Jul; 74(1):57-62. PubMed ID: 29576265
[TBL] [Abstract][Full Text] [Related]
19. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
20. First-line pembrolizumab plus chemotherapy for extensive-stage small-cell lung cancer: a United States-based cost-effectiveness analysis.
Zhu Y; Hu H; Ding D; Li S; Liao M; Shi Y; Huang J
Cost Eff Resour Alloc; 2021 Dec; 19(1):77. PubMed ID: 34863203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
